Scientists create an scRNA-seq atlas of the multiple myeloma immune microenvironment across disease stages
Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
Cancer Therapy Advisor1d
Eque-cel Elicits Responses in Heavily Pretreated Multiple Myeloma
Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.
Targeted Oncology3d
Fellow's Perspective: Patient Case of Newly Diagnosed Multiple Myeloma
MAIN: Our patient has a relatively good performance status, stage II disease ... eligible patients with newly diagnosed ...
Oncology Nurse Advisor11h
Durcabtagene Autoleucel Elicits Responses in Rel/Ref Multiple Myeloma
High rates of overall response and MRD negativity were seen regardless of the dose patients received, said Andrew Spencer, MBBS.
FiercePharma7d
J&J angles Darzalex for first move into early-stage myeloma with trial win, FDA filing
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
Targeted Oncology7h
Usmani Projects a Future of CAR T in Community for Myeloma and Other Cancers
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...
BioSpace1d
GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...